Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR - Free Report) in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biopharmaceutical company's stock.

A number of other equities research analysts also recently commented on ESPR. Needham & Company LLC dropped their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday, August 13th. StockNews.com upgraded Esperion Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $8.17.

Esperion Therapeutics Trading Up 8.1 %

ESPR stock traded up $0.17 during trading on Friday, reaching $2.28. 8,891,986 shares of the stock were exchanged, compared to its average volume of 6,165,249. The firm has a market capitalization of $447.40 million, a price-to-earnings ratio of -2.64 and a beta of 0.96. The business has a 50 day moving average price of $1.91 and a 200-day moving average price of $2.13. Esperion Therapeutics has a 1 year low of $0.87 and a 1 year high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million during the quarter, compared to analyst estimates of $51.90 million. On average, research analysts anticipate that Esperion Therapeutics will post -0.09 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Bellevue Group AG grew its holdings in shares of Esperion Therapeutics by 136.5% during the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company's stock worth $26,650,000 after buying an additional 5,739,800 shares during the last quarter. Vanguard Group Inc. raised its position in Esperion Therapeutics by 71.8% during the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company's stock worth $23,655,000 after buying an additional 3,688,796 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Esperion Therapeutics by 94.2% in the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company's stock valued at $9,554,000 after acquiring an additional 2,087,635 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Esperion Therapeutics by 3,278.3% during the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company's stock worth $1,271,000 after acquiring an additional 555,382 shares during the period. Finally, Inspire Investing LLC purchased a new position in Esperion Therapeutics during the second quarter worth about $758,000. Institutional investors and hedge funds own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.